RETA - Reata Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

0.00

Cash

330.2M

Avg Qtr Burn

N/A

Short % of Float

8.04%

Insider Ownership

4.10%

Institutional Own.

88.47%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Bardoxolone Methyl Details Chronic kidney disease, Alport Syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bardoxolone Methyl Details Autosomal Dominant Polycystic Kidney Disease, Chronic kidney disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bardoxolone Methyl Details Focal segmental glomerulosclerosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bardoxolone Methyl Details IgA nephropathy, Chronic kidney disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bardoxolone Methyl Details Type 1 diabetes, Chronic kidney disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.